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ABBREVIATIONS 
CAD          -    Coronary artery disease 
AP             -    Angina pectoris 
ACS          -    Acute coronary syndrome 
AMI          -    Acute myocardial infarction 
UA            -    Unstable angina 
STEMI      -    ST elevation MI 
NSTEMI   -     Non ST elevation MI 
HT             -    Systemic Hypertension 
DM            -    Diabetes mellitus 
WBC         -    White blood cell  
TC             -     Total count 
P                -     Polymorphs 
L                -     Lymphocytes 
E                -     Eosinophils 
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TB             -     Total bilirubin 
DB             -     Direct bilirubin 
SGOT         -     Aspartate transferase 
SGPT         -     Alanine transferase 
MPV          -     Mean platelet volume 
PDW          -     Platelet distribution width 
P-LCR       -      Platelet – Large cell ratio 
TC              -     Total cholesterol 
TGL           -      Triglycerides 
HDL          -       High density cholesterol 
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INTRODUCTION 
Acute coronary syndrome is a very important cause of 
morbidity and mortality despite the recent advances in its diagnosis 
and treatment. 
Coronary heart disease may manifest as silent myocardial 
ischemia, stable angina pectoris (AP), unstable AP, myocardial 
infarction (STEMI and NSTEMI), heart failure, and sudden cardiac 
death. 
It is important to identify the risk factors in coronary heart 
disease as they have a very important place in the prevention of 
acute coronary syndromes, and  also in the follow-up and treatment 
of patients with coronary heart disease. 
Platelets play a critical role in the formation of thrombus on 
the ruptured plaque and subsequent progression to myocardial 
infarction.  Hence, acetyl salicylic acid, thienopyridine, and 
glycoprotein IIb/IIIa inhibitors, which all inhibit platelet functions, 
are used in the treatment of ACS.  
Platelets are heterogeneous in size, density, and activity. 
Alterations of these parameters may be associated with pulling the 
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trigger of acute coronary syndrome and its spread. Large platelets 
are more adhesive and tend to aggregate more than smaller ones. 
Increase of platelet volume may contribute to increased 
prothrombotic tendency of atherosclerotic plaque in acute coronary 
syndrome and increased risk of intracoronary thrombus formation 
in AMI cases. 
In this study, we aimed to investigate the significance of 
mean platelet volume and acute coronary syndrome, in comparison 






AIMS AND OBJECTIVES OF THE STUDY 
 
1) To study the significance of mean platelet volume and acute 
coronary syndrome. 
2) To compare mean platelet volume in ACS,  stable angina 
pectoris and healthy controls. 
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REVIEW OF LITERATURE 
CORONARY ARTERY DISEASE is a major cause of 
morbidity and mortality in any part of world.  The better known 
risk factors are 
1) Age 
2) Family history 
3) Cigarette smoking 
4) Elevated LDL cholesterol  
5) Hypertension 
6) Diabetes mellitus which is accepted to be a  coronary heart 
disease equivalent. 
Apart from these,   
a. Lipoprotein (a) 
b. Endothelial dysfunction 
c. Homocysteine 
d. C Reactive protein   are considered as new risk factors of 
coronary heart disease.  
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These risk factors account for only a part of ACS cases. 
Hence, it is essential to identify other related risk factors to predict 
individual risk in the development of ACS. 
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ACUTE MYOCARDIAL INFARCTION1 
 Aspects of Diagnosis of Myocardial Infarction by Different 
Techniques 
TECHNIQUE FEATURES 
Pathology Myocardial cell death 
Biochemistry Markers of myocardial cell death recovered from blood samples 
Electrocardiography 
Evidence of myocardial ischemia (ST and T 
wave abnormalities); evidence of loss of 
electrically functioning cardiac tissue (Q 
waves) 
Imaging Reduction or loss of tissue perfusion; cardiac wall motion abnormalities 
REVISED DEFINITION OF MYOCARDIAL INFARCTION1 
Criteria for Acute, Evolving, or Recent MI 
Either of the following criteria satisfies the diagnosis for 
acute, evolving, or recent MI: 
1) Typical rise and/or fall of biochemical markers of myocardial 
necrosis with at least one of the following:  
a. Ischemic symptoms 
b. Development of pathologic Q waves in the ECG 
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c. Electrocardiographic changes indicative of ischemia (ST-
segment elevation or depression) 
d.  Imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality 
2) Pathologic findings of an acute myocardial infarction 
CRITERIA FOR HEALING OR HEALED MYOCARDIAL 
INFARCTION1 
Any one of the following criteria satisfies the diagnosis for 
healing or healed myocardial infarction: 
1) Development of new pathologic Q waves in serial ECGs. The 
patient may or may not remember previous symptoms. 
Biochemical markers of myocardial necrosis may have 
normalized, depending on the length of time that has passed 
since the infarction developed. 
2) Pathologic findings of a healed or healing infarction 
CLASSIFICATION OF MYOCARDIAL INFARCTION1 
TYPE FEATURES 
1 
Spontaneous myocardial infarction related to ischemia 
caused by a primary coronary event such as plaque erosion 




Myocardial infarction secondary to ischemia caused by 
increased oxygen demand or decreased supply (e.g., 
coronary artery spasm, coronary embolism, anemia, 
arrhythmias, hypertension, hypotension) 
3 
Sudden unexpected cardiac death, including cardiac arrest, 
often with symptoms suggestive of myocardial ischemia, 
accompanied by presumably new ST-segment elevation, or 
new LBBB, or presumably new major obstruction in a 
coronary artery by angiography and/or pathology, but death 
occurring before blood samples could be obtained, or before 
the appearance of cardiac biomarkers in the blood 
4a Myocardial infarction associated with PCI 
4b Myocardial infarction associated with stent thrombosis, as documented by angiography or autopsy 
5 Myocardial infarction associated with CABG 
CABG = coronary artery bypass grafting; LBBB = left bundle 
branch block. 
PATHOLOGY OF AMI2 
STEMI usually occurs when coronary blood flow decreases 
abruptly after a thrombotic occlusion of a coronary artery 
previously affected by atherosclerosis. A slowly developing, high-
grade coronary artery stenosis does not typically precipitate STEMI 
because of the development of a rich collateral network over time. 
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Instead, STEMI occurs when a coronary artery thrombus develops 
rapidly at a site of vascular injury. This injury is produced or 
facilitated by factors such as cigarette smoking, hypertension, and 
lipid accumulation2.  
STEMI occurs when the surface of an atherosclerotic plaque 
becomes disrupted (exposing its contents to the blood) and 
conditions (local or systemic) favor thrombogenesis. A mural 
thrombus forms at the site of plaque disruption, and the involved 
coronary artery becomes occluded. Histologic studies indicate that 
the coronary plaques prone to disruption are those with a rich lipid 
core and a thin fibrous cap2.  
After an initial platelet monolayer forms at the site of the 
disrupted plaque, various agonists (collagen, ADP, epinephrine, 
serotonin) promote platelet activation. After agonist stimulation of 
platelets, thromboxane A2 (a potent local vasoconstrictor) is 
released, further platelet activation occurs, and potential resistance 
to fibrinolysis develops2. 
In addition to the generation of thromboxane A2, activation of 
platelets by agonists promotes a conformational change in the 
glycoprotein IIb/IIIa receptor. Once it is converted to its functional 
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state, this receptor develops a high affinity for soluble adhesive 
proteins (integrins) such as fibrinogen. Since fibrinogen is a 
multivalent molecule, it can bind to two different platelets 
simultaneously, resulting in platelet cross-linking and aggregation2. 
The coagulation cascade is activated on exposure of tissue 
factor in damaged endothelial cells at the site of the disrupted 
plaque. Factors VII and X are activated, ultimately leading to the 
conversion of prothrombin to thrombin, which then converts 
fibrinogen to fibrin. Fluid-phase and clot-bound thrombin 
participate in an auto amplification reaction leading to further 
activation of the coagulation cascade. The culprit coronary artery 
eventually becomes occluded by a thrombus containing platelet 
aggregates and fibrin strands.2 
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DEFINITION1 
STABLE angina pectoris typically manifests as a deep, 
poorly localized chest or arm discomfort (rarely described as pain), 
reproducibly precipitated by physical exertion or emotional stress, 
and relieved within 5 to 15 minutes by rest or sublingual 
nitroglycerin. 
UNSTABLE angina is defined as angina pectoris (or 
equivalent type of ischemic discomfort) with at least one of three 
features:  
1) Occurring at rest (or minimal exertion) and usually lasting 
>20 minutes (if not interrupted by the administration of a 
nitrate or an analgesic) 
2) Being severe and usually described as frank pain and of new 
onset (within 1 month).      
3) Occurring with a crescendo pattern (i.e., pain that awakens 
the patient from sleep or that is more severe, prolonged, or 
frequent than previously).  
Approximately two thirds of patients with unstable angina 
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have evidence of myocardial necrosis on the basis of elevated 
cardiac serum markers, such as cardiac-specific troponin T or I and 
creatine kinase isoenzyme (CK)–MB, and thus have a diagnosis of 
NSTEMI. As troponin measurements become progressively more 
sensitive, an increasing fraction of patients with NSTE-ACS exhibit some 
release of troponin, and therefore these should be considered cases of 
NSTEMI with a reciprocal reduction in the fraction with unstable angina. 




Class I New onset of severe angina or accelerated angina; no rest pain 
Class II 
Angina at rest within past month but not 
within preceding 48 hr (angina at rest, 
subacute) 
Class III Angina at rest within 48 hr (angina at rest) 
Clinical Circumstances 
A) Secondary angina 
Develops in the presence of extra cardiac 
condition that intensifies myocardial 
ischemia 
B) Primary angina Develops in the absence of extra cardiac condition 
C) Post infarction angina Develops within 2 wk after acute myocardial infarction 
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CLASS DEFINITION 
Intensity of treatment 
Patients with unstable angina may also 
be divided into three groups according to 
whether unstable angina occurs: (1) in 
the absence of treatment for chronic 
stable angina, (2) during treatment for 
chronic stable angina, or (3) despite 
maximal anti-ischemic drug therapy. The 
three groups may be designated by 
subscripts 1, 2, and 3, respectively. 
Electrocardiographic 
changes 
Patients with unstable angina may be 
further divided into those with or 
without transient ST-T wave changes 
during pain. 
UA/NSTEMI = unstable angina/non–ST elevation myocardial 
infarction. 
PATHOLOGY OF UNSTABLE ANGINA/NSTEMI2 
 UA/NSTEMI is most commonly caused by a reduction in 
oxygen supply and/or by an increase in myocardial oxygen demand 
which is superimposed on a lesion that causes coronary arterial 
obstruction, usually an atherothrombotic coronary plaque.   
Four pathophysiologic processes that may contribute to the 
development of UA/NSTEMI have been identified2:  
1) Plaque rupture or erosion with a superimposed nonocclusive 
thrombus, believed to be the most common cause; in such patients, 
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NSTEMI may occur with downstream embolization of platelet 
aggregates and/or atherosclerotic debris  
2) Dynamic obstruction e.g., coronary spasm, as in Prinzmetal's 
variant angina (PVA) 
3) Progressive mechanical obstruction e.g., rapidly advancing 
coronary atherosclerosis or restenosis following percutaneous 
coronary intervention (PCI)   
4) UA secondary to increased myocardial oxygen demand and/or 
decreased supply e.g., tachycardia, anemia 
More than one of these processes may be involved.2 
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CARDIAC BIOMARKERS 
The ACC and AHA guidelines recommend cTnI or cTnT as 
the preferred first-line markers, but CK-MB (by mass assay) is an 
acceptable alternative. The preference for cardiac troponins reflects 
the greater specificity of these markers compared with CK-MB and 
the prognostic value of troponin elevations in the presence of 
normal CK-MB levels. If the initial set of markers is negative in 
patients who have presented within the first 6 hours of the onset of 
pain, the guidelines recommend that another sample be drawn in the 
time frame of 8 to 12 hours after symptom onset. 
Cardiac-specific Troponin T (cTnT) and Cardiac specific 
Troponin I (cTnI) have amino-acid sequences different from those 
of the skeletal muscle forms of these proteins. These differences 
permitted the development of quantitative assays for cTnT and cTnI 
with highly specific monoclonal antibodies. Since cTnT and cTnI 
are not normally detectable in the blood of healthy individuals but 
may increase after STEMI to levels >20 times higher than the upper 
reference limit (the highest value seen in 99% of a reference 
population not suffering from MI), the measurement of cTnT or 
cTnI is of considerable diagnostic usefulness, and they are now the 
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preferred biochemical markers for MI. The cardiac troponins are 
particularly valuable when there is clinical suspicion of either 
skeletal muscle injury or a small MI that may be below the 
detection limit for creatine phosphokinase (CK) and its MB 
isoenzyme (CKMB) measurements, and they are, therefore, of 
particular value in distinguishing UA from NSTEMI. Levels of 
cTnI and cTnT may remain elevated for 7–10 days after STEMI.2 
CK rises within 4–8 h and generally returns to normal by 48–
72 h. An important drawback of total CK measurement is its lack of 
specificity for STEMI, as CK may be elevated with skeletal muscle 
disease or trauma, including intramuscular injection. The MB 
isoenzyme of CK has the advantage over total CK that it is not 
present in significant concentrations in extra cardiac tissue and, 
therefore, is considerably more specific. However, cardiac surgery, 
myocarditis, and electrical cardioversion often result in elevated 
serum levels of the MB isoenzyme. A ratio (relative index) of 
CKMB mass: CK activity 2.5 suggests but is not diagnostic of a 










Many hospitals are using cTnT or cTnI rather than CKMB as 
the routine serum cardiac marker for diagnosis of STEMI, although 
any of these analytes remain clinically acceptable. It is not cost-
effective to measure both a cardiac-specific troponin and CKMB at 
all time points in every patient. 
While it has long been recognized that the total quantity of 
protein released correlates with the size of the infarct, the peak 
protein concentration correlates only weakly with infarct size. 
Recanalization of a coronary artery occlusion (either spontaneously 
or by mechanical or pharmacologic means) in the early hours of 
STEMI causes earlier peaking of biomarker measurements  because 
of a rapid washout from the interstitium of the infarct zone, quickly 
overwhelming lymphatic clearance of the proteins. 
The non-specific reaction to myocardial injury is associated 
with polymorphonuclear leukocytosis, which appears within a few 
hours after the onset of pain and persists for 3–7 days; the white 
blood cell count often reaches levels of 12,000–15,000/dL. The 
erythrocyte sedimentation rate rises more slowly than the white 
blood cell count, peaking during the first week and sometimes 
remaining elevated for one or two weeks2. 
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Serum myoglobin and heart-type fatty acid binding protein 
(H-FABP) are smaller molecules and diffuse through interstitial 
fluids more rapidly after cell death than the larger CK and troponin 
molecules; they become abnormal as early as 30 minutes after 
myocardial injury. Because neither is specific to myocardial tissue, 
however, false-positive rates in Emergency Department populations 
are high. 
Ischemia-modified albumin (IMA) has been approved by the 
U.S. Food and Drug Administration for clinical use. The albumin 
cobalt binding test for the detection of IMA is based on the 
observation that the affinity of the N-terminus of human albumin 
for cobalt is reduced in patients with myocardial ischemia. As with 
the other markers, however, the clinical specificity of IMA in the 
broad population of patients with chest pain and suspected ACS 
remains an area for further investigation. 
B-type natriuretic peptides (BNP and N-terminal pro-BNP 
[NT-proBNP]) arise in the setting of increased ventricular wall 
stress. Natriuretic peptides are most commonly used to aid in the 
diagnosis of heart failure. BNP levels can be elevated in the setting 
of transient myocardial ischemia, and the magnitude of elevation in 
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ACS is correlated with prognosis. However, the lack of specificity 
of natriuretic peptide elevation for ACS limits its use as a 
diagnostic marker. 
          Many patients presenting with ACS, including those 
without evidence of myocyte necrosis, have elevated concentrations 
of inflammatory biomarkers such as C-reactive protein, serum 
amyloid A, myeloperoxidase, or interleukin-6 (IL-6). To date, no 
study has identified exact decision cut points or shown an 
incremental benefit on an admission or treatment strategy based on 
these new markers, so the clinical usefulness of these observations 
remains uncertain. 
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LIPIDS AND MI 
During the first 24 to 48 hours after admission, total 
cholesterol and high-density lipoprotein (HDL) cholesterol remain 
at or near baseline values but generally fall precipitously after that. 
The fall in HDL cholesterol after STEMI is greater than the fall in 
total cholesterol; thus, the ratio of total cholesterol to HDL 
cholesterol is no longer useful for risk assessment unless measured 
early after MI. A lipid profile should be obtained on all STEMI 
patients who are admitted within 24 to 48 hours of symptoms. The 
success of lipid-lowering therapy in primary and secondary 
prevention studies and evidence that hypolipidemic therapy 
improves endothelial function and inhibits thrombus formation 
indicate that early management of serum lipids in patients 
hospitalized for STEMI is advisable.  For patients admitted beyond 
24 to 48 hours, more accurate determinations of serum lipid levels 





Platelets are disc-shaped, anucleate cell fragments that are shed 
from megakaryocytes in the bone marrow into the blood stream. They 
play a critical role in normal hemostasis, by forming the hemostatic plug 
that initially seals vascular defects, and by providing a surface that 
recruits and concentrates activated coagulation factors. Their function 
depends on several glycoprotein receptors, a contractile cytoskeleton, and 
two types of cytoplasmic granules. α-Granules have the adhesion 
molecule P-selectin on their membranes and contain fibrinogen, 
fibronectin, factors V and VIII, platelet factor 4 (a heparin-binding 
chemokine), platelet-derived growth factor (PDGF), and transforming 
growth factor-β (TGF-β). Dense (or δ) granules contain ADP and ATP, 
ionized calcium, histamine, serotonin, and epinephrine3. 
   After vascular injury, platelets encounter Extra cellular 
matrix constituents such as collagen and the adhesive glycoprotein 
vWF. On contact with these proteins, platelets undergo: 
1) Adhesion and shape change,  
2) Secretion (release reaction), and  
3) aggregation  
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Platelet adhesion to Extra cellular matrix is mediated largely 
via interactions with vWF, which acts as a bridge between platelet 
surface receptors (e.g., glycoprotein Ib [GpIb]) and exposed 
collagen. Although platelets can also adhere to other components of 
the ECM (e.g., fibronectin), vWF-GpIb associations are necessary 
to overcome the high shear forces of flowing blood. Reflecting the 
importance of these interactions, genetic deficiencies of vWF or its 
receptor (Bernard-Soulier syndrome) result in bleeding disorders3. 
Secretion (release reaction) of both granule types occurs soon 
after adhesion. Various agonists can bind platelet surface receptors 
and initiate an intracellular protein phosphorylation cascade 
ultimately leading to degranulation. Release of the contents of 
dense-bodies is especially important, since calcium is required in 
the coagulation cascade, and ADP is a potent activator of platelet 
aggregation. ADP also begets additional ADP release, amplifying 
the aggregation process. Finally, platelet activation leads to the 
appearance of negatively charged phospholipids (particularly 
phosphatidylserine) on their surfaces. These phospholipids bind 
calcium and serve as critical nucleation sites for the assembly of 
complexes containing the various coagulation factors3. 
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Platelet aggregation follows adhesion and granule release. In 
addition to ADP, the vasoconstrictor thromboxane A2 is an 
important platelet-derived stimulus that amplifies platelet 
aggregation, which leads to the formation of the primary hemostatic 
plug. Although this initial wave of aggregation is reversible, 
concurrent activation of the coagulation cascade generates 
thrombin, which stabilizes the platelet plug via two mechanisms3. 
      First, thrombin binds to a protease-activated receptor on 
the platelet membrane and in concert with ADP and TxA2 causes 
further platelet aggregation. This is followed by platelet activation, 
an event that is dependent on the platelet cytoskeleton that creates 
an irreversibly fused mass of platelets, which constitutes the 
definitive secondary hemostatic plug3. 
Second, thrombin converts fibrinogen to fibrin in the vicinity 
of the platelet plug, functionally cementing the platelets in place. 
The interplay of platelets and endothelium has a profound 
impact on clot formation. The endothelial cell-derived 
prostaglandin PGI2 (prostacyclin) inhibits platelet aggregation and 
is a potent vasodilator; conversely, the platelet-derived 
prostaglandin TxA2 activates platelet aggregation and is a 
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vasoconstrictor. Effects mediated by PGI2 and TxA2 are exquisitely 
balanced to effectively modulate platelet and vascular wall 
function: at baseline, platelet aggregation is prevented, whereas 
endothelial injury promotes hemostatic plug formation. The clinical 
utility of aspirin (an irreversible cyclooxygenase inhibitor) in 
persons at risk for coronary thrombosis resides in its ability to 
permanently block platelet TxA2 synthesis. Although endothelial 
PGI2 production is also inhibited by aspirin, endothelial cells can 
resynthesize active cyclooxygenase and thereby overcome the 
blockade. In a manner similar to PGI2, endothelial-derived nitric 
oxide also acts as a vasodilator and inhibitor of platelet 
aggregation3. 
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MEAN PLATELET VOLUME 
 Platelets are heterogeneous in their size, density, and 
functional activity19.  Alterations in these parameters may result as 
pulling the trigger of acute coronary syndrome and its spread20 .  
 As atherosclerotic plaque rupture begins the thrombogenic 
phenomenon in ACS, the functional activity of circulating platelets 
plays vital role in the progression of thrombus formation21.     
Large platelets are more adhesive and tend to aggregate more 
than smaller platelets as assessed by in vitro aggregometry. They 
also exhibit increased levels of procoagulatory surface proteins 
such as P-selectin and glycoprotein IIIa. Increase in platelet volume 
may contribute to increased prothrombotic tendency of 
atherosclerotic plaque in acute coronary syndrome and increased 
risk burden of intracoronary thrombus formation in Acute 
myocardial infarction cases5. 
Platelet volume is an important indicator of platelet function 
and activation. Larger platelets have more secretory granules and 
mitochondria and are more active than the small platelets. As they 
lead to the formation and dissemination of intracoronary thrombus, 
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larger and hyperactive platelets  accelerate the emergence of acute 
coronary syndrome.  
 It has been suggested that increased platelet volume 
measured after MI might be a determinant factor for future 
ischemic episodes and outcome.  
Because MPV is a simple and inexpensive laboratory 
measurement, it might be considered a useful rule-out test along 
with other conventional cardiac biomarkers for the risk 
stratification of ACS patients admitted to the emergency 
departments. 
 A study showed MPV had great diurnal and nocturnal 
variation that can be attributed to alterations in the autonomic 
nervous system46. 
It has been show that there is a correlation between 
sympathetic activity and MPV in AMI patients. It can be explained 
by the effects of the adrenergic system on peripheral platelet 
activation and thrombopoiesis in bone marrow.  
The effects of the adrenergic system occurs in two ways in 
the peripheral circulation.    
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1) Platelet activation via alpha2-adrenoreceptor activation 
changes the shape and hence increases MPV.  
2) Larger, activated platelets which are sequestered in the spleen 
can be released into the circulation following exercise or 
following administration of adrenaline, and leads to the 
increase in MPV following physical effort46.     
It has been shown that admission MPV in AMI patients is an 
independent factor for impaired reperfusion and related mortality. 
MPV measurement is an easy and feasible way to detect high-risk 













MEAN PLATELET VOLUME45 
The mean platelet volume result is calculated and produced 
by an automated analyzer, and is a calculation of the average size 
of  platelets, whereas MCV is a calculation of the average size of 
individual red blood cells. 
Normal Range7.5-11.5 fl 
If MPV is reduced  
It implies the platelets are smaller than normal. They are 
known as Micro thrombocytes45.  
CAUSES:- 
1. Aplastic Anemia -  
An acquired disorder in which the bone marrow stops 
producing new blood cells. 
2. Wiskott-Aldrich Syndrome -  
An inherited immune deficiency disease. 
3. Thrombocytopenia-absent radii (TAR Syndrome) -  
A rare inherited disorder in which there are low platelets and 
absence of the radius bones in the forearms.  
4. Storage Pool Disease -  
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A mild bleeding disorder that causes bruising. 
If MPV is increased  
It implies the platelets are larger than normal. They are 
known as Macro thrombocytes45.  
CAUSES:- 
1. Idiopathic Thrombocytopenic Purpura -  
A bleeding disorder in which the blood does not clot. 
2. Bernard-Soulier Disease -  
A congenital disorder where the platelets lack receptors to 
adhere to the walls of the blood vessels. 
3. May-Hegglin Anomaly -  
A rare, inherited disorder characterized by abnormally large 
platelets. 
4 Greater risk of heart attacks and stroke-  
As there are increased numbers of large, hyperaggregable 
platelets  there is increased risk of ischemic events. 
MPV is known to be increased in patients at the time of 
admission for MI, and it is postulated that alterations in the entire 
megakaryocyte-platelet-hemostatic axis precede MI. 
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 MPV increases before MI for three reasons46:  
1) The life span of platelets is approximately eight days, and the 
increase in MPV is seen within the first 12 h of admission 
2) The increase in MPV persists six weeks after discharge when 
the infarct would be largely healed 
3) Log normality of platelet volume is preserved.  
Recent studies have revealed the in vitro data on the 
therapeutic effects on platelet size of Losartan, an angiotensin II 
receptor antagonist, or Doxazosin, an alpha1-adrenoreceptor 
antagonist. These observations have not yet been confirmed. In a 
small study with 30 patients, found platelet aggregation inhibitors 
have no effect on MPV values5. 
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MATERIALS AND METHODS 
SETTING 
This study is conducted in Cardiology department (CCU & 
OP) and Medicine department of Madras medical college in 




This study was conducted over a period of 7 months from 
may 2011 to November 2011. 
STUDY POPULATION 
Patients admitted with acute coronary syndromes in coronary 
care unit and medical wards, stable angina pectoris patients 
followed in cardiology op and medical op, and healthy controls in 




Acute myocardial infarction: 
Ischemic symptoms 
Development of pathologic Q waves in the ECG 
Electrocardiographic changes indicative of ischemia (ST-
segment elevation or depression) 
Imaging evidence of new regional wall motion abnormality 
  Unstable angina: 
Angina pectoris (or equivalent type of ischemic discomfort) 
with at least one of three features:  
1) Occurring at rest (or minimal exertion) and usually lasting 
>20 minutes (if not interrupted by the nitroglycerin 
administration.) 
2) Being severe and usually described as frank pain, and of new 
onset (within 1 month).      
3) Occurring with a crescendo pattern (i.e., pain that awakens 
the patient from sleep or that is more severe, prolonged, or 
frequent than previously). 
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 Stable angina pectoris: 
Deep, poorly localized chest or arm discomfort (rarely 
described as pain), reproducibly precipitated by physical exertion 
or emotional stress, and relieved within 5 to 15 minutes by rest or 
sublingual nitroglycerin in whom ECG may be normal or show 
ischemic changes. 
SAMPLING 
Patients are allotted by convenience sampling in each group. 
TYPE OF STUDY 
It is a hospital based cross sectional study. 
INCLUSION CRITERIA 
Patients with  
1. Acute myocardial infarction 
2. Unstable angina 
3. Stable angina pectoris 
4. Healthy controls 
EXCLUSION CRITERIA 
1. Sepsis, immune thrombocytopenia 
2. Severe hepatic and renal disease 
3. Patients on anti-inflammatory agents,   
4. Anti-coagulation and anti-platelet agents except aspirin. 
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SAMPLE SIZE 
50 patients admitted with ACS, 50 patients with stable angina 
pectoris and 50 healthy controls. 
METHODS 
Blood samples for Mean platelet volume were taken at the 
time of admission in all ACS patients which were examined within 
1 hour. Blood samples from Stable AP patients and healthy controls 
were also taken randomly in OP and wards and examined within 1 
hour. samples were also sent for CBC, RFT, LFT. All persons were 
subjected to ECG and ECHOCARDIOGRAPHY. Mean platelet 
volume was analysed by Automatic analyzer.   
STATISTICAL ANALYSIS  
The tests used are 
ANOVA 
Chi-square test 
Data were collected and statistical significance was analysed. 
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RESULTS 




TABLE 1.1 : 
 
 
SEX FREQUENCY PERCENTAGE 
MALE 41 82% 
FEMALE 9 18% 
TOTAL 50 100% 
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TABLE 1.2 : 
 





MALE  9.583 41 .7450 .1163 
FEMALE 9.822 9 .3232 .1077 
TOTAL 9.626 50 .6919 .0978 
TABLE 1.3:  
MPV Sum of 
squares 






.423 1 .423 .881 .353 
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                             AGE GROUP AND ACS 
TABLE 2.1 
AGE GROUP FREQUENCY PERCENTAGE 
30-40 13 26% 
41-50 20 40% 
51-60 13 26% 
61-70 3 6% 
71-80 1 2% 
TOTAL 50 100% 




TABLE 2.2 : 













TYPE OF ACS BASED ON ECG 
TABLE 3.1: 
 
MI FREQUENCY PERCENTAGE 
AWMI 16 32% 
ASMI 7 14% 
IWMI 7 14% 
IW + PWMI 4 8% 
IW+ PW+ RVMI 1 2% 
UA 15 30% 
 DIAGRAM 3: 
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HYPERTENSION AND ACS 
TABLE 4.1: 
HYPERTENSION FREQUENCY PERCENTAGE 
YES 29 58% 
NO 21 42% 







TABLE 4.2 : 













DIABETES AND ACS 
TABLE 5.1: 
DIABETIC FREQUENCY PERCENTAGE 
YES 26 52% 



















1.430 1 1.430 3.116 .084 
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PRIOR CAD AND ACS 
TABLE 6.1: 
PRIOR CAD FREQUENCY PERCENTAGE 
YES 6 12% 
NO 44 88% 
DIAGRAM 6 : 
 
TABLE 6.2 : 












SMOKING AND ACS 
TABLE 7.1: 
SMOKING FREQUENCY PERCENTAGE 
YES 30 73% 
NO 20 27% 







TABLE 7.2 : 








1.255 1 1.255 2.712 .106 
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ALCOHOL AND ACS 
TABLE 8.1: 
ALCOHOL FREQUENCY PERCENTAGE 
YES 34 82% 
NO 16 18% 








TABLE 8.2 : 














class Frequency Percentage Mortality Percentage 
1 16 45% 0 0% 
2 12 33% 1 17% 
3 4 11% 1 17% 
4 4 11% 4 66% 





TABLE 9.2 : 








2.968 3 .989 2.225 .104 
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MEAN PLATELET VOLUME IN COMPARISON 
DIAGRAM 10: 
 
TABLE 10 :  
GROUP MEAN PLATELET VOLUME (Femtolitre) 
ACS 9.6 
STABLE ANGINA 8.2 
HEALTHY CONTROL 7.9 
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ECHOCARDIOGRAPHY FINDINGS IN ACS 
TABLE 11.1: 
Echo Frequency Percentage 
NO RWMA 13 26% 










TOTAL 50 100% 
RWMA- REGIONAL WALL MOTION ABNORMALITY  
DIAGRAM 11 : 
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TABLE 11.2 : 







4.326 4 1.081 2.544 .052 
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MEAN PLATELET VOLUME IN ACS 
TABLE 12.1: 







DIAGRAM 12 : 
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TABLE 12.2 : 







.860 5 .172 .335 .889 
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PLATELET COUNT IN COMPARISON 
TABLE 13: 
PLATELET COUNT MEAN  cells/dl 
ACS 2,15,340 
STABLE ANGINA PECTORIS 2,26,740 
HEALTHY CONTROLS 2,13,880 
DIAGRAM 13 : 
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MPV PDW P-LCR IN COMPARISON 
TABLE 14: 
 
MPV – MEAN PLATELET VOLUME 
PDW – PLATELET DISTRIBUTION WIDTH 






DIAGRAM 14 : 
GROUP MPV(fl) PDW% P-LCR 
ACS 9.6 14.2 29.2 
STABLE AP 8.2 12.9 24.7 
HEALTHY CONTROLS 7.9 13.1 23.5 
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OUTCOME AND DEATH  
TABLE 15.1: 
OUTCOME FREQUENCY PERCENTAGE 
IMPROVED 44 88 
EXPIRED 6 12 






TABLE 15.2 : 







2.246 1 2.246 5.084 .029 
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MPV AND DEATH 
TABLE 16: 
PATIENT NAME DEATH MPV(femtolitre) 
MARIMUTHU AWMI 9.6 
BALAJI AWMI 9.8 
FATHIMA ASMI 10.2 
YUVACHANDRAN IWMI 10.4 
DEVAN IW+PWMI 10.8 
MUNUSAMY IW+PW+RVMI 9.8 
DIAGRAM 16 : 
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                COMPARISON OF GROUPS BY MPV 
TABLE 17: 
 P-value Sig/ Not Sig
ACS group
9.6 ± 0.7  
Stable  
AP group: 8.2 ± 0.6 0.000 Sig 
Stable AP group
8.2 ± 0.6 
Control  
group: 7.9 ± 0.5 0.006 Sig MPV (Fl) 
ACS group
9.6 ± 0.7  
Control 
group: 7.9 ± 0.5 0.000 Sig 
          
TABLE 18: 
COMPARISON OF GROUPS BY MEAN PLATELET COUNTS 
 P-value Sig/ Not Sig
ACS group 
215340 ± 63491.5
Stable AP group 
226740 ± 49723.6 0.524 Not Sig
Stable AP group 
226740 ± 49723.6
Control group 






213880 ± 41747.8 0.989 Not Sig
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DISCUSSION 
In our study, three groups were taken into account.  Acute 
coronary syndrome, stable angina pectoris and healthy controls 
respectively. 
In our study the significance of mean platelet volume in acute 
coronary syndrome is the prime concern and they were compared 
with the other two groups. 
Samples for Mean platelet volume were taken at the time of 
admission in ACS group. MPV was reported by automatic analyzer. 
Statistical significance in MPV was analysed in each group.   
AGE AND MPV IN ACS  
Mean age of patients who sustained ACUTE CORONARY 
SYNDROME  was 48 in my study. Mean age in male was 46.7% 
and female was 52.4%. Mean age in males is less than that of 
female. No statistical significance was detected in MPV between 
various age groups in relation to ACS (p value is .587 i.e. >.05). 
SEX DISTRIBUTION AND MPV IN ACS 
Out of 50 patients,  41(82%) were males and 9(18%) were 
females. In a study5  the 70.8% were males.  No statistical 
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significance was detected in MPV between the two sexes in relation 
to ACS (p value is .353 i.e. >.05). 
 
TYPE OF ACS 
In my study, out of 50 ACS patients,  16(32%) had AWMI,    
7(14%) had ASMI,   7(14%) had IWMI,   4(8%) had IW+PWMI,   
1(2%) had IW+PW+RVMI and   15(30%) had UNSTABLE 
ANGINA. 
HYPERTENSION AND MPV IN ACS 
       29(58%) were hypertensive and 21(42%) were non-
hypertensive. In a similar study5 et al 60% were males. No 
statistical significance was detected in MPV between the 
hypertensive and non-hypertensive in relation to ACS (p value is 
.401 i.e. >.05). 
 
DIABETES AND MPV IN ACS 
26 (52%) were diabetic and 24(48%) were non diabetic. In a 
similar study5 36.2% were diabetic. No statistical significance was 
detected in MPV between diabetics and non-diabetics in relation to 
ACS (p value is .084 i.e. >.05). 
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SMOKING AND MPV IN ACS 
30(73%) were smoker out of 41 males. None of the females 
were smokers.  20(82%) were non-smoker. No statistical 
significance was detected in MPV between smokers and non-
smokers in relation to ACS (p value is .106 i.e. >.05). 
 
ALCOHOL AND MPV IN ACS 
34 (68%) were consuming alcohol and 16(32%) did not 
consume alcohol.  No statistical significance was detected in MPV 
between alcoholics and non-alcoholics in relation to ACS (p value 
is .937 i.e. >.05). 
 
KILLIP CLASSIFICATION AND MPV IN ACUTE 
MYOCARDIAL INFARCTION 
Patients were divided into 4 based on this classification.  15 
(45%) were in    Class 1, 12 (33%) were in class 2, 4 (11%) were in 
class 3 and 4(11%) were in   class 4.  No statistical significance 
was detected in MPV between the various killip groups in relation 
to ACS (p value is .104 i.e. >.05). 
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KILLIP CLASSIFICATION AND OUTCOME IN ACUTE 
MYOCARDIAL INFARCTION 
Patients in each killip class were analysed for death as 
outcome. Out of the total    0 (0%) death in class 1,     1 (8%) death 
in class 2,    1 (25%) death in class 3 and      4 (100%) deaths in 
class 4 occurred. 
ECHO FINDINGS AND MPV IN ACS  
In our study, echo findings were analysed. 13 (26%) had NO 
RWMA, 11(22%) had RWMA, 11(22%) had MILD LV 
DYSFUNCTION, 8(16%) had MODERATE LV DYSFUNCTION, 
7(14%) had   SEVERE LV DYSFUNCTION. No statistical 
significance was detected in MPV between various echo findings in 
relation to ACS (p value is .052 i.e. >.05). 
 
MEAN PLATELET VOLUME 
Our study showed that mean platelet volume (Femtolitres) in 
ACS group was 9.6, STABLE AP group was 8.2   and HEALTHY 
CONTROLS was 7.9. Mean platelet volume were comparable 
between ACS and STABLE AP with statistically significant 
difference of 0.000(<0.5). Similarly mean platelet volume were 
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comparable between STABLE AP AND HEALTHY CONTROLS 
with significant difference of 0.006(<0.5),  ACS and HEALTHY 
CONTROLS with significant difference of 0.000(<0.5). 
In a similar study4 which compared unstable AP and AMI 
patients, MPV in unstable AP was   9.0 ± 1.0 fl,   and 8.9 ± 0.8 fl in 
AMI patients. MPV were similar between these two groups with no 
statistically significant difference p=0.999. 
In stable AP patients, MPV as 7.5 ± 0.6 fl and 7.2 ± 0.6 fl in 
control group, respectively. MPV were comparable between these 
two groups with no statistically significant difference p=0.126. 
When unstable angina pectoris and AMI cases were compared 
to each of stable angina pectoris and control groups, it was 
observed that MPV was increased. 
Here in our study too, there is statistically significant 
difference between ACS and other two groups which is similar to 
the above cited study4. 
In the study by Endler et al10, compared AMI patients to those 
with stable AP, found MPV to be increased which is consistent with 
our study. 
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In the study by Kishk et al24. which compared AMI patients to 
stable angina pectoris and control groups detected that the former 
group had lower platelet count and higher MPV than the latter 
groups. In our study, mean platelet volume was higher in AMI 
group than others but platelet count was not reduced. 
  The study by Puzzili et al36. found that MPV was higher in 
unstable angina pectoris patients, compared to stable angina and 
control groups which is consistent with our study. 
MEAN PLATELET VOLUME IN ACS 
   In our study mean platelet volume in AWMI was 9.6,  
ASMI was 9.6, IWMI was 9.7, IW+PWMI was 10.0,  
IW+PW+RVMI was 9.8 and UA was 9.5. No statistical significance 
was detected in MPV between the various types of ACS (p value is 
.889 i.e. >.05).  
PLATELET COUNT AND ACS 
In our study, platelet counts in three groups were analysed. 
Mean value in ACS group was  2,15,340 cells/dl,   STABLE AP 
was 2,26,740 cells/dl and HEALTHY CONTROLS was 2,13,880 
cells/dl. While comparing between the groups there was no 
statistical difference between any groups. 
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In a similar study4 unstable AP patients, mean platelet count 
was 239.6 ± 59.2 x 109 /L respectively; and 228.5 ± 74.1 x 109/L in 
AMI patients. Mean platelet count was similar between these two 
groups with no statistically significant difference p=0.791. 
In stable AP patients, mean platelet count was detected as 
268.3 ± 73.5 x 
109/L, and 285.5 ± 80.9 x 109/L in control group, 
respectively. Mean platelet count was comparable between these 
two groups with no statistically significant difference p=0.586. 
When unstable angina pectoris and AMI cases were compared 
to each of stable angina pectoris and control groups, it was 
observed that platelet counts were decreased. 
Hence in our study the results were not convincing while 
comparing to the above study in terms of platelet count. 
PLATELET DISTRIBUTION WIDTH AND ACS  
In our study mean value of in ACS group was 14.2%, 
STABLE AP was 12.9% and HEALTHY CONTROLS was 13.1%. 
PLATELET-LARGE CELL RATIO AND ACS 
In our study mean value of P-LCR in ACS group was 29.2,  
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STABLE ANGINA was 24.7 and  HEALTHY CONTROLS was 
23.5. 
OUTCOME AND MPV IN ACS 
In our study, 6(12%) patients expired and 44(88%) survived 
out of 50 in the ACS group. Statistical significance was detected in 
MPV between the outcomes in relation to ACS (p value is .029      
i.e. < .05). 
It is revealed from the study that MPV is increased in ACS 
group in comparison with stable angina pectoris and healthy 
controls. Statistical difference has been showed in MPV between 
the groups.  
 
 72
LIMITATIONS OF STUDY 
1) MPV has been reported to be dependent on a number of 
variables 
a. Time of analysis after venipuncture, 
b. Method of analysis,  
c. Anticoagulant used  
d. Specimen storage temperature. 
2) The population studied is small when compared to other 
studies. 
3) Cardiac biomarkers were not done for all the patients. 
4) Coronary angiography was not done for all the patients. 
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CONCLUSION 
1) Mean platelet volume was found to be increased in ACS group 
when compared to Stable angina pectoris and Healthy controls. 
2) Statistically significant difference in mean platelet volume was 
found between the three groups respectively. 
 
3) Mean platelet volume is an easy and feasible test, it can be used as 
along with other cardiac biomarkers in patients coming with chest 
pain to evaluate for acute coronary syndrome. 
4) More comprehensive studies are required to further evaluate of the 
beneficial effects of platelet aggregation inhibitors or other drugs 
on patients with increased MPV. 
     NAME  AGE   SEX PRESENTATION DURATION HYPERTENSION DIABETES PRIOR CAD SMOKING ALCOHOL BPmm hg PULSE KILLIP THROMBOLYSIS
Loganathan 30 M AWMI 4 hrs NO NO NO YES YES 100/70 108 3 YES
Vasu 43 M ASMI 12 hrs YES NO NO YES YES 130/80 102 2 YES
Paramasivam 46 M IWMI 5 NO YES NO NO YES 120/80 96 2 YES
Varadharaj 55 M AWMI 4 YES YES NO YES YES 150/90 96 1 YES
Amulu 62 F UA 8 NO NO YES NO NO 110/80 102 1 YES
Devan 36 M IW+PWMI 3 NO YES NO NO NO 100/80 40 3 YES
Chittibabu 68 M IWMI 7 YES NO NO YES YES 120/80 72 1 YES
Fathima 54 F ASMI 5 YES YES NO NO NO 80/? ? 4 NO
Saravanan 35 M AWMI 4 NO NO NO YES YES 150/90 102 1 YES
Gopal 40 M UA 8 YES NO NO NO YES 110/90 96 NO
Ramadoss 47 M UA 4 YES YES NO YES YES 160/90 102 NO
Saseeb 52 M AWMI 10 NO YES NO YES YES 140/80 120 2 YES
Velu 56 M AWMI 6 YES YES NO YES YES 120/80 108 1 YES
Ravi 42 M IWMI 4 YES NO NO YES NO 110/80 96 2 YES
Mariammal 45 F AWMI 6 YES NO YES NO NO 100/70 102 1 YES
Vimala 54 F IW+PWMI 4 NO YES NO NO YES 100/80 108 2 YES
Raji 50 M UA 4 YES YES NO YES YES 160/100 96 NO
Yuvachandran 58 M IWMI 5 YES YES NO YES YES 100/60 84 2 YES
Vinayagam 38 M UA 7 NO NO NO YES NO 130/90 102 NO
Thangadurai 36 M UA 4 YES NO NO YES YES 110/80 108 NO
Veeramani 40 M UA 11 YES NO NO NO NO 120/80 96 NO
Nidhi 42 M AWMI 6 NO NO YES YES NO 110/80 102 1 YES
Panneer 50 M ASMI 5 YES YES NO YES YES 150/90 96 2 YES
Raja 65 M UA 5 NO YES NO NO YES 110/90 102 NO
Balaji 39 M AWMI 6 NO YES NO YES YES 60/? ? 4 NO
Kani 48 M AWMI 8 YES YES NO NO YES 200/100 120 3 NO
Parasuram 56 M IW+PWMI 6 YES NO NO YES YES 90/60 54 3 YES
Prabakar 40 M UA 7 YES NO NO YES YES 160/90 108 NO
Parameswari 46 F ASMI 5 NO YES NO NO NO 110/80 96 1 YES
Rathinavel 54 M UA 4 NO NO NO NO YES 150/90 96 NO
James 50 M UA 1 YES YES NO YES YES 140/90 102 NO
Vetri 34 M IWMI 4 NO NO NO YES YES 100/80 96 1 YES
Munusamy 42 M I+P+RVMI 3 YES YES NO YES YES 70/? ? 4 NO
Vennila 56 F AWMI 6 NO NO NO NO NO 160/100 108 1 YES
Sivasankaran 48 M UA 6 YES NO YES NO YES 150/100 102 NO
Munivel 44 M AWMI 4 NO NO NO YES YES 140/90 96 1 YES
Pankajam 37 F ASMI 5 YES YES NO YES NO 210/110 108 2 NO
Ismail 49 M AWMI 3 NO YES NO YES YES 160/90 120 1 YES
Veerammal 74 F UA 8 YES NO NO NO NO 160/100 102 NO
Vendhan 44 M UA 12 NO YES NO YES YES 130/90 96 NO
Karthik 60 M AWMI 5 YES NO YES NO NO 110/70 96 1 YES
     NAME  AGE   SEX PRESENTATION DURATION HYPERTENSION DIABETES PRIOR CAD SMOKING ALCOHOL BPmm hg PULSE KILLIP THROMBOLYSIS
Mohammad 54 M IWMI 4 YES YES NO YES NO 100/70 72 2 YES
Marimuthu 48 M AWMI 6 NO YES NO NO YES 70/? 126 4 NO
Palani 56 M ASMI 8 YES NO NO NO YES 170/100 64 2 YES
Veeraragavan 39 M IW+PWMI 4 NO YES NO YES YES 130/90 102 1 YES
Ayyadurai 45 M UA 4 NO YES NO YES YES 110/70 102 NO
Venda 44 F ASMI 3 YES NO NO NO NO 110/80 96 1 YES
Periasamy 52 M IWMI 5 YES YES NO NO YES 110/80 108 1 YES
Annamalai 40 M AWMI 10 NO YES NO YES YES 100/80 120 2 YES




MILD LV DYSFUNCTION 3
MODERATE 4
SEVERE 5




SUGAR   UREA CREATININE     TB    DB     OT     PT      TC   TGL   HDL   MPV  PDW  P-LCR ECHO HOSPITAL STAY OUTCOME
12000 72 26 2 204000 84 25 0.8 1.1 0.3 42 46 158 124 46 10.9 15.6 37.6 3 7 SURVIVED
9600 68 30 2 186000 96 30 0.9 1 0.1 44 45 240 164 48 9.2 14.2 29.2 2 5 SURVIVED
9700 66 30 4 126000 128 32 1 0.9 0.1 45 44 168 96 66 11.3 17.6 40.2 3 6 SURVIVED
8600 72 26 2 304000 192 28 0.9 0.9 0.1 45 46 170 130 64 8.9 12.8 26.2 4 5 SURVIVED
11000 66 33 1 208000 102 30 0.8 0.8 0.1 44 45 220 140 32 10.2 14.8 35.6 1 7 SURVIVED
9600 74 24 2 192000 284 40 1.1 1 0.2 42 45 186 100 30 10.8 13.6 36.6 5 1 EXPIRED
7200 72 26 2 174000 106 26 0.8 1 0.1 42 46 240 124 56 9.6 13.3 28.8 3 6 SURVIVED
YES 8400 66 30 3 120000 204 32 0.9 0.8 0.1 40 42 154 108 45 10.2 14.8 36.8 5 1 EXPIRED
9400 64 33 3 304000 104 28 0.6 0.9 0.1 46 44 120 120 34 8.4 12.6 26.2 2 6 SURVIVED
YES 7200 70 26 4 286000 84 28 0.8 0.8 0.1 46 44 189 165 60 9.2 14 28.2 1 5 SURVIVED
YES 8900 64 33 3 204000 236 30 1 1 0.2 45 43 224 148 42 8.6 12.8 27 2 5 SURVIVED
7400 66 32 2 124000 164 40 1.2 1 0.1 44 40 174 130 64 9.8 14.2 29.2 3 6 SURVIVED
9400 56 40 4 240000 198 42 1.2 0.8 0.1 42 45 154 142 60 10 14.8 32.2 2 5 SURVIVED
7000 68 30 4 194000 90 26 0.8 0.8 0.1 44 47 220 180 40 9.2 13.6 28.6 4 6 SURVIVED
8200 70 28 2 300000 110 22 0.6 0.9 0.1 46 42 185 156 46 9.4 13.2 26 4 7 SURVIVED
9900 68 26 6 120000 140 28 0.6 0.8 0.2 45 44 140 174 48 9.8 14.4 28.2 4 6 SURVIVED
YES 7600 69 30 1 181000 264 34 1.2 1 0.2 48 46 185 125 40 10.2 16 30.2 1 5 SURVIVED
8200 64 34 2 240000 240 34 1.4 0.8 0.1 45 48 235 158 43 10.4 15.4 31.2 5 14 HRS EXPIRED
YES 8600 60 34 6 288000 80 26 0.8 0.8 0.1 46 45 180 124 43 9.6 14.2 28.4 1 6 SURVIVED
YES 7400 68 30 2 150000 196 28 0.8 0.9 0.1 42 40 186 180 47 7.8 12.4 27.4 1 5 SURVIVED
YES 6200 66 30 4 186000 106 30 1 1.1 0.2 44 40 214 124 59 9.6 13.8 27.8 2 5 SURVIVED
8000 64 32 4 240000 146 24 0.6 1.2 0.2 46 45 164 168 50 8.8 13.2 25.4 2 7 SURVIVED
7400 80 16 4 186000 102 28 0.6 0.8 0.1 48 46 175 145 60 9.2 14.4 26.4 3 7 SURVIVED
YES 9400 69 28 3 360000 290 36 1.2 0.8 0.1 44 48 240 186 44 9.6 14.8 28.2 1 5 SURVIVED
YES 9800 54 40 6 172000 146 40 1.4 0.9 0.1 40 45 146 190 56 10.2 15.8 30.4 5 5 EXPIRED
YES 8800 68 29 3 268000 380 42 1.4 0.9 0.1 42 47 246 159 55 9.4 13.4 28.4 4 6 SURVIVED
9000 62 32 6 142000 76 28 0.8 1.2 0.2 46 43 198 137 43 10.4 15 31.8 5 12 SURVIVED
YES 6800 72 22 6 246000 120 30 0.8 0.8 0.1 40 45 174 186 42 10.2 14.2 30.2 2 6 SURVIVED
7200 66 32 2 190000 138 34 1.2 0.9 0.1 45 46 236 124 48 9.8 13.8 26.8 2 7 SURVIVED
YES 9200 69 28 3 320000 82 24 0.8 1 0.1 42 42 149 170 65 8.9 13.6 25.9 1 5 SURVIVED
YES 8600 64 32 4 178000 190 34 1 1 0.2 40 48 248 158 40 9.6 14.2 27.8 1 5 SURVIVED
9400 71 26 3 240000 102 24 1 0.9 0.2 44 49 246 140 42 8.8 13.4 27.2 4 8 SURVIVED
YES 9200 70 28 2 181000 166 38 1.4 0.8 0.1 46 45 149 268 44 9.8 14.2 28.6 5 12 HRS EXPIRED
8400 68 28 4 120000 88 22 0.8 0.8 0.1 44 42 154 124 50 10.2 14.8 31.8 2 6 SURVIVED
YES 8540 66 30 4 342000 92 24 0.8 1 0.1 42 40 248 182 54 9.6 13.9 27.8 1 6 SURVIVED
7000 66 30 4 196000 110 30 1 1.1 0.2 40 46 196 196 54 8.8 13.2 25.4 2 5 SURVIVED
YES 9200 64 32 4 246000 168 34 1 1 0.2 42 45 224 145 40 9.4 14 28.2 3 6 SURVIVED
8600 66 32 2 180000 124 40 1.4 1 0.1 44 42 184 158 42 10.8 15.4 30.4 3 5 SURVIVED
YES 9600 59 36 5 274000 102 28 0.8 0.8 0.1 43 48 154 120 65 9.8 14.6 28.2 1 5 SURVIVED
YES 8400 68 30 2 144000 254 36 1.4 0.9 0.1 42 49 169 142 44 10.2 14.8 30.2 1 5 SURVIVED
8300 62 32 6 268000 84 28 0.8 0.7 0.1 46 42 154 280 42 9.2 14.2 28.4 1 5 SURVIVED




SUGAR   UREA CREATININE     TB    DB     OT     PT      TC   TGL   HDL   MPV  PDW  P-LCR ECHO HOSPITAL STAY OUTCOME
9500 64 32 4 172000 174 30 1 0.8 0.1 44 46 236 146 50 8.6 12.8 26.2 3 7 SURVIVED
YES 6900 66 33 1 189000 190 36 1.2 1 0.2 41 48 185 120 64 9.8 14.8 27.2 5 9 HRS EXPIRED
6400 70 28 2 348000 106 26 0.8 0.9 0.1 42 46 174 100 44 9.6 13.6 26.8 3 6 SURVIVED
9000 68 30 2 169000 280 30 0.8 0.9 0.1 40 45 145 126 48 8.9 13.2 25.6 4 7 SURVIVED
YES 8200 60 36 4 283000 254 34 1.2 1 0.1 44 42 280 124 42 9.6 14.6 28.4 1 5 SURVIVED
6400 64 32 4 182000 78 28 0.6 0.7 0.1 45 47 184 158 48 9.6 14.4 27.6 3 5 SURVIVED
7600 66 32 2 170000 102 40 1.2 0.8 0.2 44 41 149 224 42 10.4 15.4 29.8 4 6 SURVIVED
8400 68 30 2 240000 220 42 1.2 0.7 0.1 42 48 210 124 40 9.2 14.8 28.8 3 7 SURVIVED
8200 66 31 3 190000 108 28 0.8 0.8 0.1 44 46 168 140 64 9.8 15 29.2 2 5 SURVIVED
NAME AGE SEX HYPERTENSION DIABETES SMOKING ALCOHOL TOTAL COUNT P L E
Vikram 24 M NO NO NO YES 8000 56 40 4
Nalan 25 M NO NO YES YES 7000 66 32 2
Saravanan 29 M YES NO YES NO 8000 77 30 3
Zaheer 30 M NO NO YES YES 7700 74 22 4
Velammal 30 F YES NO NO NO 7600 65 33 2
Saradha 32 F NO YES NO NO 6800 62 36 2
Ragavan 32 M YES NO YES YES 6450 70 28 2
Thiagu 32 M YES YES YES YES 7800 62 26 2
Ranjith 32 M NO NO YES NO 6600 66 32 2
Kannadasan 33 M NO NO YES NO 7500 68 30 2
Vivek 34 M NO NO YES YES 6800 70 26 4
Baby 34 F NO NO NO NO 6400 64 32 4
Bama 34 F NO NO NO NO 5000 62 36 2
Saradhammal 34 F NO NO NO NO 8800 68 30 2
Karuppusamy 35 M NO NO YES YES 7800 74 22 4
Basker 35 M NO YES YES YES 5600 62 38 2
Varadhan 35 M NO YES YES NO 6800 64 32 4
Jaiganesh 35 M NO NO YES YES 8500 66 30 4
Bakkiam 35 F NO NO NO NO 6400 66 30 4
Ramesh 35 M YES NO YES YES 9900 68 30 2
Rani 36 F YES YES NO NO 8400 60 36 4
Ellammal 36 F NO NO NO NO 6600 64 32 4
Veeramani 36 M NO NO NO YES 10200 70 28 2
Kali 38 M NO NO NO YES 6200 70 26 4
Ravi 38 M NO NO NO YES 7200 62 36 2
Mangammal 38 F YES NO NO NO 6800 70 28 2
Sulaiman 38 M YES NO NO NO 7480 66 30 4
Mani 38 M YES YES YES YES 8100 70 28 2
Lalitha 38 F YES NO NO NO 5800 72 26 2
Velu 38 M NO NO YES NO 6600 62 36 2
Nandakumar 38 M NO NO YES NO 9000 70 28 2
Sabari 40 M NO YES YES YES 6800 64 32 4
NAME AGE SEX HYPERTENSION DIABETES SMOKING ALCOHOL TOTAL COUNT P L E
Adhithan 40 M NO NO YES YES 6000 72 26 2
Esther 40 F NO NO NO NO 7100 65 31 4
Laila 40 F NO NO NO NO 9000 70 26 4
Dhandapani 40 M YES NO YES YES 7800 68 30 2
Vellaiyan 40 M YES NO YES YES 7400 70 28 2
Rajasekar 42 M NO NO NO YES 5800 66 32 4
Mayandi 44 M YES NO NO YES 6500 60 36 4
Akbar 44 M NO NO NO YES 7000 72 26 2
Soodamani 45 F NO YES NO NO 5800 78 20 2
Kannan 45 M NO NO YES YES 6800 66 30 4
Sankar 45 M YES NO NO YES 7540 65 31 4
Pandian 45 M NO YES YES YES 7500 68 30 2
Manikandan 48 M YES NO YES YES 6500 72 24 4
Kala 50 F NO NO NO NO 8100 65 30 5
Parvadham 50 F YES NO NO NO 6800 64 32 4
Veearapandi 55 M NO YES YES YES 8000 68 30 2
Sadasivam 65 M NO NO YES YES 7000 62 36 2




MILD LV DYSFUNCTION 3
MODERATE LV DYSFUNCTION 4
SEVERE LV DYSFUNCTION 5
PLATELET COUNT SUGAR UREA CREATININT TB DB OT PT TGL TC HDL MPV PDW P-LCR ECHO
220000 102 34 0.8 0.8 0.2 45 45 142 134 54 7.2 12.4 22.5 1
180000 98 36 1.1 0.8 0.1 40 48 100 164 52 7.4 12.6 22.4 1
200000 102 40 0.9 1 0.2 45 46 120 126 64 7.3 12.4 22.1 1
250000 98 28 0.6 0.9 0.2 50 42 112 108 45 8.2 13.4 24.2 1
220000 100 30 0.6 0.8 0.1 44 42 144 153 59 8.4 13.6 25.1 1
178000 246 24 0.8 0.8 0.2 48 40 140 165 54 8.4 14 24.5 1
240000 140 24 0.6 0.8 0.1 48 43 133 150 69 8.1 13.6 24.6 1
300000 102 28 0.6 0.9 0.1 45 48 130 200 68 7.5 12.9 22.5 1
210000 90 28 0.8 0.8 0.1 48 44 124 166 60 8 12.8 21.8 1
240000 98 28 0.6 0.9 0.1 45 45 182 155 58 7.4 12.4 21.9 1
198000 104 30 0.8 1 0.2 42 46 112 123 48 7.4 12.8 23.1 1
164000 84 38 0.8 0.9 0.2 40 47 154 120 68 7.8 13 22.5 1
145000 102 26 0.8 0.8 0.1 46 42 120 162 68 7.7 12.9 23.1 1
220000 114 24 0.8 0.8 0.1 48 46 102 165 48 8.2 13.8 25.4 1
168000 89 24 0.8 1 0.1 45 48 135 184 65 7.6 12.6 22.4 1
240000 120 28 0.8 0.8 0.1 49 48 144 165 62 7 12.1 21.4 1
240000 182 34 0.9 0.9 0.2 42 48 144 124 60 7.6 12.4 23.4 1
190000 114 34 0.8 0.8 0.2 45 48 122 179 62 7.8 12.5 22.3 1
180000 96 22 0.9 1 0.1 45 42 120 157 66 7.9 13.4 23.7 1
204000 98 32 0.6 1 0.2 44 44 120 175 65 8.1 13.6 24.5 1
212000 96 32 0.9 0.9 0.1 48 42 135 168 56 7.8 12.8 22.9 1
168000 98 28 0.8 1 0.3 40 48 156 135 56 7.2 13.2 22.1 1
190000 86 28 0.8 0.9 0.1 42 45 130 168 62 8.5 14.1 25.6 1
260000 88 34 0.6 0.9 0.1 42 46 100 123 64 8.2 13.8 24.1 1
200000 84 30 0.8 1 0.1 40 49 142 120 54 7.2 12.1 22.4 1
200000 96 26 0.8 0.8 0.1 44 40 100 135 56 8.1 13.9 24.5 1
240000 100 28 0.8 0.9 0.1 48 42 130 168 68 8.2 13.5 24.2 1
148000 80 38 0.6 0.7 0.2 44 50 134 240 60 8.2 13.6 24.5 1
280000 104 28 0.8 0.8 0.1 46 40 120 158 68 7.9 13.1 23.1 1
146000 90 24 0.8 0.8 0.1 40 44 102 153 48 8.9 14 26.5 1
290000 88 38 0.6 0.8 0.1 40 44 134 148 64 7.8 13.2 23.5 1
198000 126 30 0.6 0.8 0.1 48 48 120 169 54 8.2 13.8 24.9 1
PLATELET COUNT SUGAR UREA CREATININT TB DB OT PT TGL TC HDL MPV PDW P-LCR ECHO
180000 84 24 0.8 0.7 0.2 46 49 122 154 69 7.6 12.2 22.9 1
180000 89 34 0.6 0.8 0.1 44 48 124 158 54 7.9 12.4 22.6 1
340000 102 39 1 0.8 0.2 48 49 130 164 65 8.3 13.5 24.8 1
280000 88 26 0.8 1 0.2 44 45 110 189 60 7.4 12.7 22.7 1
240000 98 30 1 0.7 0.1 40 42 102 185 58 7.8 13.2 22.7 1
212000 102 30 0.6 0.9 0.1 45 42 150 124 68 7.6 12.4 22.8 1
190000 142 26 0.9 0.8 0.2 44 47 126 147 56 7.8 12.6 22.9 1
200000 76 28 0.6 0.8 0.1 48 42 132 186 67 8.2 13.8 24.4 1
200000 148 28 0.8 1 0.1 45 45 142 124 65 9.2 14.2 27.5 3
168000 98 34 0.8 0.9 0.1 42 45 142 195 64 7.5 12.7 22.1 1
200000 86 24 0.7 0.7 0.1 40 44 124 124 62 7.8 12.4 22.6 1
260000 140 30 0.8 0.9 0.1 42 40 100 146 56 8.1 13.4 24.8 1
250000 88 26 0.8 0.9 0.1 40 45 130 164 59 9.1 14.4 27.5 1
245000 142 35 1 1 0.1 46 49 100 154 54 6.8 11.8 21.4 3
180000 86 32 0.7 1 0.2 44 48 104 129 62 7.5 12.8 22.9 1
250000 86 30 0.9 1 0.2 45 46 122 124 58 8.5 14.6 25.1 1
180000 88 28 0.9 1 0.1 44 44 132 142 50 7.8 13.4 22.9 1
220000 124 32 1 0.9 0.2 42 45 120 168 68 7.6 12.8 21.8 3
NAME AGE SEX YPERTENSI DIABETESSMOKINGALCOHOL BP PULSE TOTAL COUN P L E ATELET COU
Subramani 40 M YES NO YES NO 110/80 90 7400 66 32 2 250000
Thirulokchander 55 M NO NO NO NO 120/90 96 8400 64 34 2 246000
Ettiappan 34 M NO YES YES YES 140/90 102 7000 69 28 3 348000
Sampath 45 M YES YES NO YES 150/90 90 6800 72 26 2 246000
Vanmathi       58 F YES NO NO NO 120/80 90 6400 70 26 4 184000
Pradeep 60 M YES NO YES YES 110/90 84 7200 68 30 2 222000
Madasamy 38 M NO NO YES NO 110/90 96 7800 66 30 4 150000
Kavitha 50 F NO YES NO NO 120/80 96 6200 64 32 4 186000
Seethammal 42 F YES YES NO NO 160/100 90 9000 60 36 4 240000
Rajavel 40 M YES NO NO YES 140/90 90 5400 68 30 2 240000
Kannappan 56 M YES NO YES NO 120/90 102 8000 67 30 3 310000
Patrik 35 M NO YES YES NO 130/90 78 7400 66 31 3 180000
Raja 38 M YES NO NO YES 140/90 84 6800 58 36 6 168000
Mumtaj 45 F YES NO NO NO 110/90 84 7400 66 32 4 240000
Makimairaj 40 M NO YES NO YES 110/90 90 8000 69 30 1 256000
Chandran 30 M NO YES YES YES 120/80 78 7400 67 30 3 190000
Parthasarathy 36 M YES NO YES YES 130/90 72 7200 72 26 2 168000
Kamatchi 34 F NO NO NO NO 120/80 84 8000 71 26 3 280000
Kanagaraj 72 M NO YES YES NO 120/90 90 8100 68 30 2 220000
Siva 50 M YES NO YES YES 140/90 84 6900 69 28 3 196000
Elavarasan 45 M NO NO YES NO 110/80 78 8200 65 30 5 150000
Mala 38 F NO NO NO NO 120/90 96 8400 58 36 6 268000
Latha 54 F YES NO NO NO 160/90 84 6900 70 28 2 240000
Stalin 35 M YES NO YES YES 140/90 78 7500 70 28 2 300000
Kalaivani 48 F YES NO NO NO 140/90 72 7700 72 26 2 190000
Veera 46 M YES YES YES NO 110/90 90 8000 66 30 4 178000
Karunakaran 38 M YES NO NO YES 140/80 84 9200 68 30 2 250000
Vanitha 40 F YES YES NO NO 150/90 102 8600 64 32 4 286000
Lingam 44 M YES YES YES YES 110/80 96 8400 72 22 6 175000
Elumalai 38 M NO NO YES YES 110/80 90 7500 70 26 4 200000
Thiruveni 50 F NO YES NO NO 130/90 84 6800 66 30 4 280000
NAME AGE SEX YPERTENSI DIABETESSMOKINGALCOHOL BP PULSE TOTAL COUN P L E ATELET COU
Vetrivel 52 M YES YES YES YES 150/90 90 8500 68 30 2 159000
Ayyanar 46 M YES YES YES NO 100/80 90 7900 68 30 2 180000
Geetha 38 F NO YES NO NO 100/80 78 5800 59 38 3 290000
Parthiban 45 M YES YES NO YES 140/90 78 7500 70 28 2 286000
Raniammal 40 F NO YES NO NO 110/80 72 8100 70 28 2 190000
Imran 37 M YES YES YES YES 150/80 84 6800 64 32 4 286000
Janakiraman 39 M YES YES YES YES 110/80 90 7400 66 32 4 290000
Babu 46 M NO YES NO YES 110/80 84 8000 66 30 4 195000
Joseph 67 M YES NO YES YES 150/90 78 5900 68 30 2 184000
Vadivu 60 F YES NO NO NO 160/100 90 6400 70 28 2 290000
Rathinam 54 M NO NO YES NO 120/80 90 6800 68 26 6 200000
Velmurugan 50 M YES NO YES YES 110/80 78 7200 70 28 2 185000
Ramasamy 38 M NO NO NO YES 120/80 72 8100 74 32 4 208000
Karuthamma 49 F NO NO NO NO 120/90 78 6800 69 30 1 195000
Kalimuthu 40 M NO YES YES YES 110/80 84 5700 66 30 4 280000
Deenadayalan 38 M YES YES YES YES 170/100 90 8200 64 32 4 200000
Venkat 56 M YES NO YES NO 140/90 78 7500 66 30 4 156000
Parameswaran 48 M YES NO YES YES 130/90 84 8400 60 36 4 286000




MILD LV DYSFUNCTION 3
MODERATE LV DYSFUNCTION 4
SEVERE LV DYSFUNCTION 5
SUGAR UREAREATINI TB DB OT PT TC TGL HDL MPV PDW P-LCR ECHO
96 28 0.6 0.9 0.1 34 36 186 120 64 7.8 11.8 23.2 1
102 30 0.8 0.9 0.2 36 38 154 140 66 8.2 12.4 25.6 1
110 26 0.9 0.8 0.1 40 40 200 112 54 7.6 11.8 22.9 1
90 30 1 1 0.1 39 35 240 162 68 8 12.6 23.5 1
80 32 0.6 0.7 0.1 38 36 186 140 44 9.2 13.8 27.2 1
109 22 0.5 0.8 0.2 35 38 154 100 40 8.8 12.8 25.8 1
120 28 0.8 0.8 0.2 34 39 170 114 58 7.6 12.2 22.8 1
180 22 0.4 0.9 0.1 36 35 164 125 44 8.4 12.8 25.5 1
102 26 0.6 0.8 0.1 39 34 200 142 52 8.2 11.9 24.9 3
99 30 1 1 0.2 35 38 140 105 44 9.4 14 28.2 1
140 32 0.9 1 0.1 38 35 184 134 48 7.4 11.6 22.5 1
110 28 0.8 0.8 0.1 37 35 154 110 62 8.2 12.6 24.6 1
98 25 0.8 0.9 0.1 35 38 164 142 42 8.6 12.8 25.2 1
108 22 0.6 0.7 0.1 36 39 174 186 40 7.9 11.8 22.4 1
240 26 0.8 1 0.2 40 42 180 120 48 8.4 12.6 24.4 1
98 30 0.8 1.1 0.3 42 40 240 135 58 9.1 13.9 27.2 1
134 32 0.9 0.9 0.2 44 48 148 140 56 8.6 12.5 25.4 1
86 32 1 0.9 0.1 41 40 168 120 66 7.9 11.8 22.8 1
145 24 0.8 0.8 0.1 40 38 148 100 68 7.6 12 22.4 3
84 22 0.8 0.9 0.2 35 39 164 124 59 8.2 12.6 24.8 1
90 28 0.8 1 0.1 36 38 200 135 67 8.8 13.4 25.2 1
90 30 1 0.8 0.1 38 38 154 142 45 9.2 14.2 28 1
110 30 0.9 1.1 0.2 36 40 186 108 68 8.6 13.8 25.4 1
85 24 0.6 0.8 0.1 34 40 248 154 56 8.8 14 25.1 1
80 24 0.8 0.9 0.2 40 42 174 120 68 7.6 12.4 22.4 1
148 22 0.8 0.8 0.1 42 39 164 220 64 9 14.2 27.4 1
125 29 1 0.8 0.1 35 38 180 145 50 8.4 13.6 25.2 1
220 21 0.6 0.9 0.2 36 38 142 168 40 7.8 12.8 22.6 3
96 20 0.6 0.9 0.2 38 40 175 120 54 8 12.2 24.8 1
142 28 0.8 1 0.1 34 40 164 109 64 8.2 12.6 24.8 1
102 25 0.8 1 0.2 42 38 234 120 48 8.6 13.4 25.4 1
SUGAR UREAREATINI TB DB OT PT TC TGL HDL MPV PDW P-LCR ECHO
245 23 0.6 0.8 0.1 40 38 182 107 44 8.2 13.4 25.6 3
140 22 0.8 0.7 0.1 42 42 168 132 46 7.4 12.2 22.8 1
96 28 1 0.7 0.1 40 39 124 110 40 7.2 11.9 22.4 1
186 26 0.8 0.9 0.2 30 35 169 122 56 9.2 14.2 27.5 1
120 24 0.8 1 0.1 35 40 174 114 58 8.4 12.8 25.6 1
155 21 0.6 0.9 0.2 36 40 242 158 45 8.6 13.2 25.2 1
84 28 1 0.9 0.1 35 38 154 164 44 7.2 12.1 22.6 4
98 34 1.2 0.8 0.1 34 38 280 100 64 8 13.2 24.8 1
80 28 0.9 1 0.2 40 42 146 175 40 7.8 12.4 22.6 1
140 36 0.8 0.8 0.1 42 38 225 122 48 7.4 12.2 23 1
90 29 0.8 0.9 0.2 42 36 146 104 68 8.2 13.2 24.4 1
79 21 0.6 0.8 0.1 35 40 154 112 50 8.6 13.4 25.2 3
110 30 0.8 0.7 0.1 36 42 220 145 52 9.4 14.2 28.2 1
84 34 1 0.9 0.2 38 40 188 119 44 7.6 11.9 22.4 1
190 27 0.6 1 0.1 48 38 168 124 58 8.2 13.3 24.8 1
154 25 0.8 0.9 0.2 42 40 169 104 40 8.4 13.9 25.2 1
98 34 1.1 1 0.1 42 38 245 144 42 7.8 12.8 22.8 1
88 26 0.8 0.9 0.1 40 38 180 186 64 8.2 13.4 25.8 1
124 28 0.9 0.8 0.2 47 46 165 180 58 8.4 13.8 25.6 1
 
